Travere Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
CA
Business Address
3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130
Mailing Address
3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130
Phone
888-969-7879
Fiscal Year End
1231
EIN
262383102
Financial Overview
FY2025
$605.19M
Total Assets
$200.81M
Stockholders' Equity
$-0.29
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 10-K Annual financial report | February 19, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- Achieved 35% revenue growth in 2025, reaching $385 million, primarily driven by strong FILSPARI sales.
- Maintained a healthy financial position with $280 million in cash and successfully refinanced $150 million in Senior Notes.
Insider Trading
STRONG SELL
7 insiders
28 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.